Please use this identifier to cite or link to this item: https://doi.org/10.1186/1471-2164-15-S9-S20
Title: Novel SNP improves differential survivability and mortality in non-small cell lung cancer patients
Authors: Mah, T.L
Yap, X.N.A
Limviphuvadh, V
Li, N
Sridharan, S
Kuralmani, V
Feng, M 
Liem, N
Adhikari, S
Yong, W.P 
Soo, R.A 
Maurer-Stroh, S 
Eisenhaber, F 
Tong, J.C 
Keywords: DNA directed DNA polymerase alpha
gemcitabine
deoxycytidine
DNA directed DNA polymerase beta
gemcitabine
tumor marker
adult
aged
Article
cancer mortality
cancer survival
carcinogenesis
cellular distribution
clinical article
confocal laser microscopy
controlled study
DNA replication
female
genetic association
genetic variability
human
human cell
male
non small cell lung cancer
oncogene
outcome assessment
overall survival
POLA2 gene
protein analysis
protein localization
single nucleotide polymorphism
survival time
active transport
analogs and derivatives
biology
Carcinoma, Non-Small-Cell Lung
cell nucleus
chemical structure
chemistry
genetics
genotype
Lung Neoplasms
metabolism
middle aged
mortality
mutation
prognosis
protein conformation
survival
Active Transport, Cell Nucleus
Adult
Aged
Biomarkers, Tumor
Carcinoma, Non-Small-Cell Lung
Cell Nucleus
Computational Biology
Deoxycytidine
DNA Polymerase I
Female
Genotype
Humans
Lung Neoplasms
Male
Middle Aged
Models, Molecular
Mutation
Polymorphism, Single Nucleotide
Prognosis
Protein Conformation
Survival Analysis
Issue Date: 2014
Publisher: BioMed Central Ltd.
Citation: Mah, T.L, Yap, X.N.A, Limviphuvadh, V, Li, N, Sridharan, S, Kuralmani, V, Feng, M, Liem, N, Adhikari, S, Yong, W.P, Soo, R.A, Maurer-Stroh, S, Eisenhaber, F, Tong, J.C (2014). Novel SNP improves differential survivability and mortality in non-small cell lung cancer patients. BMC Genomics 15 (9) : S20. ScholarBank@NUS Repository. https://doi.org/10.1186/1471-2164-15-S9-S20
Abstract: Background: Non-small cell lung cancer (NSCLC) is a major cause of cancer-related death worldwide due to poor patient prognosis and clinical outcome. Here, we studied the genetic variations underlying NSCLC pathogenesis based on their association to patient outcome after gemcitabine therapy. Results: Bioinformatics analysis was used to investigate possible effects of POLA2 G583R (POLA2+1747 GG/GA, dbSNP ID: rs487989) in terms of protein function. Using biostatistics, POLA2+1747 GG/GA (rs487989, POLA2 G583R) was identified as strongly associated with mortality rate and survival time among NSCLC patients. It was also shown that POLA2+1747 GG/GA is functionally significant for protein localization via green fluorescent protein (GFP)-tagging and confocal laser scanning microscopy analysis. The single nucleotide polymorphism (SNP) causes DNA polymerase alpha subunit B to localize in the cytoplasm instead of the nucleus. This inhibits DNA replication in cancer cells and confers a protective effect in individuals with this SNP. Conclusions: The results suggest that POLA2+1747 GG/GA may be used as a prognostic biomarker of patient outcome in NSCLC pathogenesis. © 2014 Mah et al.; licensee BioMed Central Ltd.
Source Title: BMC Genomics
URI: https://scholarbank.nus.edu.sg/handle/10635/174295
ISSN: 14712164
DOI: 10.1186/1471-2164-15-S9-S20
Appears in Collections:Elements
Staff Publications

Show full item record
Files in This Item:
File Description SizeFormatAccess SettingsVersion 
10_1186_1471-2164-15-S9-S20.pdf536.09 kBAdobe PDF

OPEN

NoneView/Download

SCOPUSTM   
Citations

6
checked on Oct 22, 2020

Page view(s)

10
checked on Oct 22, 2020

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.